Evaluation of the Safety and Tolerability of Prucalopride in Constipated Elderly Subjects Living in a Nursing Facility - Full Text View

Purpose

The purpose of this study is to determine whether prucalopride is safe and effective in the treatment of constipation in elderly subjects living in a nursing facility.

Hypothesis:

Prucalopride up to a dose of 4 mg once daily is safe and well tolerated in in elderly subjects living in a nursing facility.

Condition	Intervention	Phase
Constipation	Drug: Prucalopride Other: Placebo	Phase 2

Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment
Official Title:	A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Tolerability of Oral Once-Daily Prucalopride (R108512) Solution in Constipated Elderly Subjects Living in a Nursing Facility

Resource links provided by NLM:

MedlinePlus related topics: Constipation

U.S. FDA Resources

Further study details as provided by Movetis:

Primary Outcome Measures:

Patient's Global Assessment of severity of constipation and efficacy of treatment evaluated (for exploratory reasons only). [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Patient's symptom assessment(evaluated for exploratory reasons only). [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

Enrollment:	100
Study Start Date:	February 1999
Study Completion Date:	May 2000
Primary Completion Date:	May 2000 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: 1 Prucalopride	Drug: Prucalopride 0.5 mg o.d. Other Name: Resolor
Active Comparator: 2 Prucalopride	Drug: Prucalopride 1 mg o.d. Other Name: Resolor
Active Comparator: 3 Prucalopride	Drug: Prucalopride 2 mg o.d. Other Name: Resolor
Placebo Comparator: 5 Placebo	Other: Placebo o.d.
Active Comparator: 4 Prucalopride	Drug: Prucalopride 4 mg o.d. Other Name: Resolor

Detailed Description:

This is a multicenter, Phase II, dose-escalation trial with a 4 week double-blind, placebo-controlled treatment period. There will be four treatment cohorts (0.5 mg, 1 mg, 2 mg, or 4 mg) with 25 subjects in each. The first cohort of 25 subjects will be randomly assigned to receive either 0.5 mg R108512 or placebo in a 4 to 1 ratio, respectively, for four weeks. After two weeks of treatment, the safety and tolerability of this dose will be evaluated for each subject by an independent (external) safety committee. If, at the completion of treatment, the safety committee grants approval to proceed to a higher dose, the second cohort will be randomly assigned to receive either 1 mg R108512 or placebo for four weeks. In a likewise manner, each dose will be evaluated for safety and tolerability before the next cohort will be treated with a higher dose. No subject can participate in more than one treatment cohort.

Subjects will be instructed not to change their diet or lifestyle during the trial. Subjects will be allowed to continue the use of routine stool softeners and fiber supplements during the trial; however, all existing stimulant or osmotic laxative medication will be withdrawn. If, during the trial, the subject does not have a complete bowel movement for three or more consecutive days, he/she will be allowed the use of his/her usual stimulant or osmotic laxative or an enema as a rescue medication. No laxatives or enemas should be used within the 24 hours before and 24 hours after the start of double-blind treatment.

Eligibility

Ages Eligible for Study:	65 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Male and female patients at least 65 years of age (no upper age limit).
History of constipation. i.e., the patient should have received any treatment for constipation at any time during the 4 weeks (28 days) preceding entry into the study, including fibre/bulk forming supplements.
The patient had to live in a nursing facility.
The patient had to be clinically stable.
The patient had to be able to take oral medications.
The patient had to be continent of bowels the majority of time.
The patient had to be able to reliably communicate AEs.
The patient had to provide informed consent, signed by the patient or legally acceptable representative and by the investigator.

Exclusion Criteria:

Patients who were known to be HIV positive or who had AIDS.
Patients who were being actively treated with Propulsid (cisapride) or cancer chemotherapy other than hormonal agents.
Patients with significantly impaired renal function, i.e., creatinine clearance <30 mL/min using the Cockcroft and Gault formula:

Males: CLCR = [(140-age) x (weight in kg)] / 72 x (SCR).

Females: CLCR = male value x 0.85

Because the calculated value for creatinine clearance could be artificially high when serum creatinine concentrations were very low, patients with a serum creatinine <0.5 mg/dL were excluded from the study.
Patients who received an investigational drug in the 30 days preceding the study.
Patients who had previously received either R093877 or R108512.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00627692

Sponsors and Collaborators

Movetis

Investigators

Principal Investigator:

D O'Neill, MD

Riverside Regional Convalescent Center

More Information

No publications provided

Responsible Party:	Renate Specht Gryp, Movetis
ClinicalTrials.gov Identifier:	NCT00627692 History of Changes
Other Study ID Numbers:	PRU-USA-26
Study First Received:	February 21, 2008
Last Updated:	May 28, 2008
Health Authority:	United States: Institutional Review Board

Keywords provided by Movetis:

Constipation in elderly patients

Additional relevant MeSH terms:

Constipation
Signs and Symptoms, Digestive
Signs and Symptoms

ClinicalTrials.gov processed this record on May 23, 2013